[Thrombolysis for ischemic stroke: an update].
Even 10 years after the approval of thrombolysis this life-saving and disability reducing therapy is still underused. Important reasons for that are very strict inclusion criteria such as the early and narrow time-window, fear of bleeding complications and doubts regarding the effectiveness. An intensive and constant effort is required to educate the public that stroke is a treatable emergency. In addition to the medical reasons, economic considerations in a context of decreasing resources emphasize the importance of effective stroke treatment. The results of numerous recent studies such as the European register SITS-MOST help to strengthen the confidence in thrombolysis. In addition the development and advancement of new imaging tools such as multiparametric MRI and advanced CT-techniques will improve patient selection and may enable us to extend the time-window for treatment. Intraarterial thrombolysis, "bridging" methods and new devices for intravascular intervention are the subjects of intensive ongoing research. Even though no randomized trials are available intraarterial thrombolysis is the treatment of choice for acute basilar occlusion, but if this intervention is not available an intravenous approach may be an equal alternative.
Köhrmann
M
M
Neurologische Universitätsklinik, Schwabachanlage 6, 91054 Erlangen. martin.koehrmann@neuro.imed.uni-erlangen.de
Jüttler
E
E
Huttner
H B
HB
Schellinger
P D
PD
D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000639:trends*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D015912:Thrombolytic Therapy / Q000379:methods* / Q000639:trends*
D005343:Fibrinolytic Agents